Effect of Ciba 13,437-Su on serum cholesterol and triglycerides, plasma fibrinogen, fibrinolysis and platelet adhesiveness in patients with ischemic heart disease

P. M. Mannucci, F. Pareti, C. A. Maggi, M. Diaguardi

Research output: Contribution to journalArticlepeer-review

Abstract

The effects of the phenolic ether Ciba 13,437-Su (300 mg daily) on serum cholesterol, triglycerides, plasma fibrinogen, fibrinolysis and platelet adhesiveness were assessed in 10 patients with ischemic heart disease treated for 6 months and observed thereafter for 2 months with a placebo. The administration of the drug was free of appreciable side-effects and no evidence of toxicity was seen. Serum transaminase did not show any significant change. Mean serum cholesterol was reduced by about 20% and serum triglycerides by about 50% after the 1st month of treatment. The decrease was sustained and the levels returned to the high initial values when the placebo was started. A progressive fall of plasma fibrinogen was also observed, attaining the lowest values after 5 months of treatment and reverting to the initial values when the active drug was withdrawn. Fibrinolysis was not favourably influenced by the drug, as seen by the prolongation of the euglobulin lysis time and the increase of plasma plasminogen. Platelet adhesiveness was not significantly changed. Hence Ciba 13,437-Su is an effective and well-tolerated agent with a sustained hypolipidemic action. However, a decrease of fibrinolytic activity during the treatment was observed.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalAtherosclerosis
Volume13
Issue number1
DOIs
Publication statusPublished - 1971

Keywords

  • Hypolipidemic agents
  • Ischemic heart disease
  • Tetraline derivative
  • Thrombogenic parameters

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of Ciba 13,437-Su on serum cholesterol and triglycerides, plasma fibrinogen, fibrinolysis and platelet adhesiveness in patients with ischemic heart disease'. Together they form a unique fingerprint.

Cite this